MGX
Metagenomi Therapeutics, Inc.
-0.00 (-0.01%)1.15USD53.5K成交股數43.4M市值–本益比(近四季)1.9股價營收比–營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | – | 1.2M-70% | 3.9M-66% | 8.7M-57% | 8.5M-24% | 4.1M-67% | 11.5M-7% | 20.0M+76% | 11.2M | 12.4M | 12.4M | 11.3M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 22.5M | 19.3M | 21.5M | 25.3M | 22.5M | 25.1M | 26.3M | 28.3M | 31.4M | 24.8M | 26.8M | 22.7M |
| 銷售管理費用 | 6.0M | 6.5M | 6.8M | 6.2M | 7.0M | 6.8M | 7.6M | 8.6M | 8.8M | 7.8M | 7.9M | 6.6M |
| 營業利益 | −28.8M+37% | −24.6M-12% | −24.4M+9% | −22.8M+35% | −21.0M-28% | −27.8M+38% | −22.4M-0% | −16.9M-6% | −29.0M | −20.2M | −22.4M | −18.0M |
| 營業利益率 | – | -1,970.1% | -623.0% | -263.8% | -246.5% | -674.1% | -194.4% | -84.3% | -260.2% | -162.9% | -181.1% | -158.4% |
| 稅後淨利 | −27.5M+38% | −23.1M-8% | −22.5M+20% | −20.4M+90% | −19.9M-21% | −25.0M+30% | −18.8M-5% | −10.7M-17% | −25.1M | −19.3M | −19.8M | −13.0M |
| 淨利率 | – | -1,847.7% | -576.0% | -235.5% | -233.9% | -606.7% | -163.0% | -53.7% | -225.4% | -155.6% | -160.3% | -114.7% |
| 稀釋 EPS | -0.73+35% | -0.61-10% | -0.59+16% | -0.55+90% | -0.54-55% | -0.68-88% | -0.51-91% | -0.29-92% | -1.19 | -5.67 | -5.82 | -3.82 |
| 稀釋股數 | 37.7M | 37.6M | 37.3M | 37.3M | 37.2M | 37.0M | 36.8M | 36.6M | 21.1M | 3.4M | 3.4M | 3.4M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 39.0M | 25.3M | 41.7M | 32.8M | 26.9M | 29.2M | 25.1M | 61.2M | 103M | 141M | 102M | 51.6M |
| 應收帳款 | 0.00 | 0.00 | 305K | 960K | 900K | 900K | 589K | 1.6M | 2.1M | 2.5M | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 174M | 197M | 221M | 248M | 272M | 298M | 358M | 386M | 415M | 365M | – | – |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 61.1M | 59.2M | 62.5M | 69.5M | 76.5M | 85.2M | 103M | 116M | 140M | 150M | – | – |
| 股東權益 | 113M | 138M | 159M | 178M | 196M | 213M | 256M | 269M | 276M | −136M | −119K | −103M |
| 負債比 | 35.2% | 30.0% | 28.3% | 28.0% | 28.1% | 28.6% | 28.6% | 30.2% | 33.6% | 41.0% | – | – |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −21.2M-7% | – | – | – | −22.8M | – | – | −29.9M | – | – | – |
| 資本支出 | – | 25K | – | – | – | 288K | – | – | 915K | – | – | – |
| 自由現金流 | – | −21.2M-8% | – | – | – | −23.1M | – | – | −30.8M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -1,698.7% | – | – | – | -560.5% | – | – | -275.7% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 25.2M | -51.8% | −87.9M | -348.5% | -2.36 | −89.5M |
| FY2024 | 52.3M | +16.8% | −78.1M | -149.3% | -2.36 | −112M |
| FY2023 | 44.8M | – | −68.3M | -152.5% | -20.05 | −101M |